Form 4: Relay Therapeutics Director Jami Rubin Granted Stock Options

Relay Therapeutics, Inc. director Jami Rubin was granted 136,681 stock options with an exercise price of $3.36, vesting on the earlier of June 6, 2026, or the next annual meeting of stockholders.

Summary

• Jami Rubin, a Director of Relay Therapeutics, Inc. (RLAY), was granted 136,681 stock options.
• The transaction date for this grant was June 6, 2025.
• The exercise price for these stock options is $3.36 per share.
• The options vest in full on the earlier of the first anniversary of the grant date (June 6, 2026) or the date of the next annual meeting of stockholders following the grant date.
• The expiration date for these stock options is June 5, 2035.
• Following this transaction, Jami Rubin beneficially owns 136,681 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is a positive for aligning interests but does not indicate significant new operational or financial developments.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• This is a standard form of compensation for directors, indicating ongoing commitment and participation in the company's equity structure.

Future Outlook

This Form 4 filing does not provide a general future outlook for the company, but it indicates future potential equity ownership for the director upon vesting and exercise of the options.

Industry Context

The grant of stock options to directors is a common practice across industries, particularly in biotechnology and pharmaceutical sectors like Relay Therapeutics, to attract and retain talent and align leadership incentives with company performance and shareholder returns.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice in the biotechnology industry, aligning with typical corporate governance and incentive structures.
• The vesting schedule, tied to either an anniversary or the next annual meeting, is also a common mechanism to ensure continued engagement and performance.

Corporate Governance

Related Party Transactions

• The grant of stock options to Jami Rubin, a director of Relay Therapeutics, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value, potentially leading to more focused efforts on increasing stock price.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation philosophy that can influence overall employee morale and retention strategies.

Next Steps

• The stock options will vest on the earlier of June 6, 2026, or the date of the next annual meeting of stockholders following the grant date.
• Upon vesting, Jami Rubin will have the right to exercise these options at $3.36 per share until June 5, 2035.

Key Dates

Keywords

Relay Therapeutics, RLAY, Stock Option, Insider Transaction, Form 4, Jami Rubin, Director, Equity Grant, Beneficial Ownership